Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males between the ages of 18 and 35~* Have acute unilateral complete ACL tears with or without bucket handle medial meniscus tears that occurred within the past 6 months~* Consent to undergo an ACL reconstruction by an orthopaedic surgeon using a patellar tendon or hamstring autograft~* Will be performing supervised post-operative rehabilitation at UMHS MedSport at Dominos Farms~Exclusion Criteria:~* Patients who are undergoing a revision ACL reconstruction~* Had a previous injury to the involved knee~* Have an allergy to recombinant GH~* Have a BMI\<20 or \>35~* Have a growth disorder of bones or connective tissue, type 1 diabetes mellitus, type 2 diabetes mellitus, or who have a history of carpal tunnel syndrome, trigger finger, myopathy, cancer, endocrine disorder, hypertension or rheumatologic disorder.~* Systolic blood pressure \>140mm Hg or diastolic blood pressure \>90mm Hg, or with resting heart rate \>110 BPM or \<40 BPM at screening.~* Additionally, because GH is currently listed as a banned substance by the World Anti-Doping Agency (WADA), National Collegiate Athletics Association (NCAA) and most professional sports agencies, we will exclude patients who are current collegiate, professional or elite athletes.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Somatropin (Type: ACTIVE_COMPARATOR): Somatropin of rDNA origin
- Placebo (Type: PLACEBO_COMPARATOR): A placebo vehicle that contains somatropin diluent but no active hormone.

Based on this trial design, predict the completion outcome and termination type (if applicable).